Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer ...

When Hurricane Helene struck in late September, it flooded the largest IV fluid factory in the United States. The Baxter International facility in western North Carolina had been producing 1.5 million ...

The patient said he had seen Dr. Robert Janisse pull out "rusty channel locks" before turning to an assistant and making a ...

The phase 3 SKYSCRAPER-01 trial of tiragolumab and atezolizumab in PD-L1-high non–small cell lung cancer did not meet its ...

It's a disease that is most common in people in their 70s, more common in women, and almost never seen below the age of 50.

Boston Scientific has signed a deal to acquire the maker of a chemotherapy infusion pump aimed at treating certain inoperable ...

Study finds perioperative pembrolizumab plus neoadjuvant chemotherapy in early-stage NSCLC is safe, effective and improves ...

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

Rahway, N.J.-based Merck said a trial of the drug, given under the skin and combined with chemotherapy, proved to be as ...

A new study published in the Journal of Neurotrauma shows that intravenous administration of immunomodulatory nanoparticles ...

Jazz Pharmaceuticals JAZZ announced that the FDA has granted accelerated approval to its intravenously administered drug ...

The JN.1 subvariant of SARS-CoV-2 emerged in late 2023 and rapidly became dominant globally. In the past 6 months, JN.1 has continued to evolve, giving rise to multiple sublineages with unique ...